Cellular Therapy
Conference Coverage
CT103A elicits responses after prior CAR T-cell relapse
BOSTON – Three of four patients who had failed a prior CAR T-cell therapy achieved a stringent complete response after CT103A.
From the Journals
CAR T-cell therapy less effective in transformed follicular lymphoma
The complete response rate and duration of response were better in patients with follicular lymphoma than in those with transformed follicular...
Conference Coverage
Low intensity bridging may be best path to CAR T in adult ALL
CHICAGO – Researchers examined the use of high- and low-intensity chemotherapy bridging for patients waiting for treatment with a CD19-directed...
News
FDA approves first drug for steroid-refractory acute GVHD
Ruxolitinib will be made available to appropriate patients immediately, according to Incyte.
Feature
CMS proposes payment increase for administering CAR T in the hospital
The CMS would raise the new technology add-on payment to hospitals for administration of CAR T-cell therapies from $186,500 to $242,450.
Feature
ICYMI: NIH renames, streamlines gene therapy committee
The Recombinant DNA Advisory Committee will now be known as the Novel and Exceptional Technology and Research Advisory Committee.
Conference Coverage
Monitoring, early intervention key to CAR T safety
GLASGOW – Dr. Loretta Nastoupil of the MD Anderson Cancer in Houston said that toxicity in CAR T-cell therapy “is something we don’t talk about as...
From the Journals
Gene therapy restored immunity in newly diagnosed SCID-X1
In the phase 1/2 study, seven infants had normal immune cells 3-4 months after treatment, while the eighth infant responded after a gene therapy...
Conference Coverage
Factors emerge for mitigating CD19 CAR T toxicity
HOUSTON – Cytokine release syndrome and neurotoxicity are common complications related to CD19-directed CAR T-cell immunotherapies, but research...
Conference Coverage
Creating CAR T-cell therapies for T-cell malignancies
NEWPORT BEACH, CALIF. – Dr. John F. DiPersio discusses preclinical research testing CAR T-cell therapies in T-cell malignancies.
From the Journals
Infant survival rate after HCT remains flat
Survival rates remained largely unchanged from 2000-2014 for infants who underwent allogeneic hematopoietic cell...